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Abstract
Introduction: Oligomeric amyloid-ß is a major toxic species associated with Alzheimer’s disease pathogenesis.
Methods used to measure oligomeric amyloid-β in the blood have increased in number in recent years. The
Multimer Detection System-Oligomeric Amyloid-β (MDS-OAβ) is a specific method to measure oligomerization
tendencies in the blood. The objective of this study was to determine the association between amyloid-ß oligomerization
in the plasma and structural changes of the brain.
Methods: We studied 162 subjects composed of 92 community-based normal healthy subjects, 17 with subjective
cognitive decline, 14 with mild cognitive impairment and 39 with Alzheimer’s disease dementia. All subjects underwent
MDS-OAβ and three-dimensional T1 magnetic resonance imaging. To determine the structural changes of the brain that
are statistically correlated with MDS-OAβ level, we used voxel-based morphometry with corrections for age and total
intracranial volume covariates.
Results: We found brain volume reduction in the bilateral temporal, amygdala, parahippocampal and lower parietal lobe
and left cingulate and precuneus regions (family-wise error, p < 0.05). Reduction was also found in white matter in
proximity to the left temporal and bilateral lower parietal lobes and posterior corpus callosum (family-wise error, p < 0.05).
Brain volume increment was not observed in any regions within grey or white matter.
Discussion: Findings suggest that substantial correlation exists between amyloid ß oligomerization in the blood and
brain volume reduction in the form of Alzheimer’s disease despite of uncertainty in the casual relationship.
Keywords: Oligomerization, Blood-based biomarker, Amyloid β, Oligomer, Multimer detection system, Voxel-
based morphometry, Multimer detection system-oligomeric Aβ
Introduction
Biomarkers play an important role in the diagnosis, sta-
ging and the risk assessment of disease. Especially, in clin-
ical trials of disease-modifying drugs for Alzheimer’s
disease (AD), the biomarker is necessary in selecting sub-
jects and predicting responders to a specific drug inter-
vention and monitoring the responsiveness. Extracellular
accumulation of amyloid-β (Aβ) plaques and intracellular
neurofibrillary tangles is the characteristic feature of AD
[1–3]. Aβ is produced by cleavage of amyloid precursor
proteins into a monomeric form by β-secretase and
γ-secretase, which is transformed into oligomeric form
and fibre form, and finally into amyloid plaques [4].
Among them, oligomeric Aβ is the major toxic species of
Aβ associated with AD pathology as well as synaptic dys-
function [5, 6], and this could be the final target of AD
biomarker. Currently validated amyloid biomarkers of AD
are cerebrospinal fluid Aβ1–42 level and amyloid positron
emission tomography imaging [7]. However, there are
some limitations, such as invasiveness, interlaboratory
variability, and cost. Many researchers have focused on
the identification of blood-based biomarkers for AD but,
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up to the present, no biomarker having a direct associ-
ation with the pathogenesis of AD has been found [8, 9].
Recently, new methods, advanced in terms of invasiveness
and cost and aimed at measuring oligomeric Aß in the
blood, emerged in numbers.
The Multimer Detection System-Oligomeric Aβ
(MDS-OAβ) is one of these promising methods for differ-
entiating AD measuring the oligomerization tendency of
spiked synthetic Aβ in the plasma [10]. This basically uti-
lizes Multimer Detection System, a sandwich assay that
uses capture antibodies and epitope-overlapping detection
antibodies to preferentially detect oligomers or multimers
from monomers in protein-misfolding diseases through
competitive bindings to specific epitopes [11–13].
MDS-OAβ basically exploits the Aß dynamic changes ob-
served in the blood of AD to measure the oligomerization
tendency. Previous reports have demonstrated the value of
MDS-OAβ in AD diagnosis by comparing it with other bio-
markers, cerebrospinal fluid (CSF) biomarkers and amyloid
positron emission tomography images but did not show
that MDS-OAβ reflects the pathological mechanism of AD
[11]. In this study, we hypothesized that higher Aß
oligomerization in the blood are associated with the neur-
onal degeneration of the brain in the form of AD. Many re-
cent studies have utilized voxel-based morphology (VBM),
an automated volumetric analysis procedure. VBM has the
advantage of being a relatively faster analysis process and
generating consistent results [14, 15]. Therefore, it was an-
ticipated that this VBM study would demonstrate correl-
ation between volume changes in cortical grey matter
(GM) and white matter (WM) and Aß oligomerization as
measured by MDS-OAß and, furthermore, relate to atro-
phic change of AD brain [16, 17].
Methods
This study was based on data obtained from one of the
‘Dementia Overcoming Projects in Korea’—a study for
the development of protein biomarkers and clinical stud-
ies for the early diagnosis of dementia, which has been
funded by the Ministry of Health & Welfare since 2015.
From May 2015 to December 2017, a total of 188 ‘cogni-
tive normal’ subjects, 38 subjects with ‘mild cognitive
impairment (MCI)’, and 202 subjects with ‘AD’ were re-
cruited in 5 disorder clinics at university-based hospitals.
A subset of this group was randomly selected and
subjected to MDS-OAβ. We analysed MRI using
voxel-based morphometry (VBM) to locate the regions
within cortical grey matter (GM) and white matter
(WM) where volume changes correlated with
MDS-OAβ levels.
Subjects
Aβ oligomerization tendency in the plasma of 187 sub-
jects was measured using MDS-OAβ; however, 25
subjects were not suitable for analysis as no
three-dimensional T1-weighted magnetic resonance im-
aging was performed. Accordingly, 162 subjects were eli-
gible for this study. The images of 12 subjects could not
be converted from the raw Digital Imaging and Commu-
nications in Medicine (DICOM) format into the Neuro-
imaging Informatics Technology Initiative (nifti) format.
Further, 10 subjects dropped out during pre-processing
due to errors, and 3 others dropped out after quality
check.
The three-dimensional T1-weighted magnetic reson-
ance imaging data of 162 subjects were from 92
community-based healthy normal controls (HNC), 38
with AD, 15 with mild cognitive impairment due to AD,
and 17 with subjective cognitive decline (SCD) (Fig. 1).
The inclusion criteria for HNC in the present study
were as follows: (1) the absence of memory complaints,
(2) normal general cognition (within 1 standard devi-
ation (SD) of the age- and education-adjusted norms of
the Korean version of the MMSE and a score > 26), (3)
intact activities of daily living (ADL), (4) Korean Demen-
tia Screening Questionnaire < 7 [18] and (5) the absence
of depression (short form geriatric depression score < 8).
The following comprise those for SCD: (1) the presence
of memory complaints; (2) normal general cognition
(within 1 standard deviation (SD) of the age- and
education-adjusted norms of the Korean version of the
MMSE (K-MMSE) [19], and a score of > 26); (3) intact
performance of daily living (ADL); and (4) no abnormal-
ity on a comprehensive neuropsychological battery
(within 1 SD of age- and education-adjusted norms)
[20]. The criteria for MCI were as follows: (1) the pres-
ence of memory complaints; (2) intact performance of
ADL; (3) objective cognitive impairment in more than
one cognitive domain on a comprehensive neuropsycho-
logical battery (at least 1.0 SD below age- and
education-adjusted norms); (4) CDR of 0.5; and (5) not
demented according to the Diagnostic and Statistical
Manual of Mental Disorders (DSM)-IV criteria. The pa-
tients with AD dementia (ADD) met the probable AD
criteria proposed by the National Institute of Neuro-
logical and Communicative Disorders and Stroke and
AD and Related Disorders Association (NINCD-
S-ADRDA) [21], as well those proposed by the DSM-IV.
The measurement of oligomerization of Aβ in plasma
MDS-OAβ was used to measure OAβ [12, 13]. For this
method, epitope-overlapping antibodies specific for the
N-terminus of Aβ were used to capture and detect the Aβ
antigen in its multimeric or oligomeric form. The mouse
monoclonal antibody 6E10 (BioLegend, San Diego, CA,
USA) and WO2-HRP antibody (Absolute Antibody Ltd.,
Oxford, UK) were chosen to detect OAβ in MDS due to
their sensitivity and specificity. The epitopes for these
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antibodies overlap at the N-terminus of Aβ. To utilize
MDS, the wells of a 96-well black plate were coated with
6E10 antibody at a dilution of 3 μg/ml in
carbonate-bicarbonate buffer (Sigma-Aldrich, St. Louis,
MO, USA) and incubated overnight at 4 °C (Thermo
Fisher Scientific, Waltham, MA, USA). The plates were
blocked for 2 h with 0.4% Block Ace (100 μl) at RT. After
washing three times with phosphate-buffered saline (PBS;
Sigma-Aldrich, St. Louis, MO, USA), the plate was stored
at 4 °C until use. Prior to the assay, aliquots of plasma
samples were thawed at 37 °C for 15min. A solution con-
taining 10 μl of plasma, 4 μl of HBR-1, a HAMA blocker
(Scantibodies Laboratory, Santee, CA, USA), and PBST
was mixed. We spiked the synthetic Aβ into plasma mix-
ture and incubated it at 37 °C for 1 h. The plasma sample
mixture and serially diluted standards were added to each
well of the plate in a total volume of 100 μl. The plates
were incubated at RT for 1 h. After washing three times
with TBST, the WO2-HRP antibody in TBST containing
0.4% Block Ace was added to the wells, and the plate was
incubated for 1 h at RT. Finally, 100 μl of 3,3′,5,5′-tetra-
methylbenzidine (TMB) reagents (Sigma-Aldrich, St.
Louis, MO, USA) was added as a substrate, and the reac-
tion was stopped with 50 μl of 1M H2SO4. Optical density
(OD) values were measured at 450 nm using a Victor
3TM multi-spectrophotometer.
Pre-processing of MRI for VBM analysis
MRI scans were acquired from 3-T scanners manufac-
tured by Philips (Achieva, Amsterdam, the Netherlands)
with the DICOM format. The data were analysed using
VBM analysis using the Computational Anatomy Tool-
box (CAT12) via the current version of Statistical
Parametric Mapping software (SPM12). CAT12 is a
VBM toolbox implemented in Statistical Parametric
Mapping software [22] for performing comprehensive
VBM analyses of brain structures, designed by The
Structural Brain Mapping Group at the University of
Jena (Jena, Germany) for automatic and easy-to-use ap-
plication [23].
First, we converted the raw DICOM files into nifti format,
using MRICRON software (http://people.cas.sc.edu/rorden/
mricron/index.html). VBM analyses were conducted using
SPM12, and pre-processing was performed through the
CAT12 toolbox with the default settings and ‘ICBM
template-East Asian Brains’ template. All scans were normal-
ized using an affine followed by non-linear registration, cor-
rected for bias field in homogeneities, and then segmented
into GM, WM and CSF components [24]. We used the Dif-
feomorphic Anatomic Registration Through Exponentiated
Lie algebra algorithm (DARTEL) to normalize the segmented
scans into a standard Montreal Neurological Institute space
[25]. The modulation process was performed, which corrects
individual differences in the brain size, consisted of a
non-linear deformation performed on the normalized seg-
mented images [26]. We reviewed the GM and WM mor-
phological abnormalities and applied smoothing processes to
all segmented, modulated and normalized GM and WM im-
ages using 8-mm full-width-half-maximum Gaussian
smoothing.
Statistical analyses
The smoothed images fed into a linear multiple regres-
sion of SPM12 to detect negative correlations between
the GM area and the level measured by MDS-OAβ. In
CAT12 toolboxes, the total intracranial volumes could
Fig. 1 Enrolment of eligible subjects
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be obtained. We used the subject’s age and total intra-
cranial volumes in the matrix design. The GM and WM
morphological differences are shown after using a
family-wise error (FWE) with a p value < 0.05. The ex-
tent threshold was set at 50 voxels.
Comparisons between MDS-OAβ levels and ages of
the groups and sex were made using the R package (R
version 3.5.1) and its library (Rcmdr 2.5-2).
Results
MDS-OAβ level of the subjects
The mean age of the subjects was 63.0 ± 9.3 (mean ±
standard deviation) years, and 98 were female and 64
male. There was no gender difference according to the
clinical states from HNC to AD (Pearson’s chi-squared
test, p = 0.719). The overall MDS-OAβ levels were 0.903
± 0.131, and there was no difference between the gender
(Welch’s two sample t test, p = 0.864). It showed ten-
dency to increase from HNC to SCD, MCI and AD
(ANOVA, p < 0.001), and there was a significant differ-
ence from MCI and AD compared to HNC level, but
there were age differences between them (Tukey mul-
tiple comparison of means, p < 0.01) (Table 1).
VBM analyses of the GM and WM
Table 2 and Fig. 2 show significant GM and WM volume
change in relation to the oligomerization level measured
by MDS-OAß and VBM analysis in all spectrum of sub-
jects which includes HNC, SCD, MCI and AD dementia.
Table 2 presents anatomic labelling of brain Montreal
Neurological Institute coordinates where reduced vol-
ume correlated to Aβ oligomerization in the blood pre-
sented in Fig. 2. The areas are statistically significant
with correction of multiple comparison problems by
FWE. The VBM analysis conducted using CAT12 re-
vealed a significant reduction in GM volume of the bilat-
eral temporal, amygdala, parahippocampal and lower
parietal lobe and left cingulate and precuneus (FWE <
0.05) (Fig. 2a). We also found WM volume reduction
nearby the left temporal and bilateral lower parietal
lobes and posterior corpus callosum (FWE, p < 0.05)
(Fig. 2b). There was not any location which showed in-
crements of the brain volume related to MDS-OAβ
levels.
Discussion
In this study, we found that blood MDS-OAβ levels had
a negative correlation with brain volume changes of spe-
cific regions; locations which showed significant volume
reduction were the bilateral hippocampus, posterior cin-
gulate and temporoparietal areas. These are typical areas
of degeneration in AD [27, 28], suggesting that the
oligomerization of Aβ in the blood can cause a pattern
of AD in the brain. We also did VBM analysis of the AD
group and found the GM volume reduction in bilateral
medial temporal, bilateral dorsolateral temporoparietal
and medial parietal areas. These regions are well known
for typical sites of degenerative changes in AD (Add-
itional file 1: Figure S1) and coincide with the sites
showing volume reduction correlating with MDS-OAß
levels. As shown in Table 1 and Additional file 2: Figure
S2, MDS-OAß levels may have been affected by the age.
However, as the design and objective of the study reside
in locating the region of atrophy of the brain in relation
to increasing MDS-OAß level as well as the region in
the brain where AD pathology occurs, the subjects’ vari-
ables were not adjusted before image analysis.
The level of MDS-OAβ may indicate the dynamics
of Aβ in the blood. When Aß oligomerization is mea-
sured after synthetic Aß is spiked into plasma and in-
cubated over time, the oligomerization dynamics
differ between AD and normal healthy subjects [10].
The characteristics of Aβ in the blood are related to
changes in brain volume. As far as we know, this is
the first study to show that oligomerization tenden-
cies in blood are related to brain volume reductions
and that this change is very similar to the brain atro-
phy patterns demonstrated in AD. This correlation
may further support the notion that peripheral blood
characteristics could relate to the central brain
Table 1 Demographics of the subjects
Subject number (female to male) MDS-OAβ Age
Sex
Female 98 0.904 ± 0.130 63.1 ± 9.6
Male 64 0.901 ± 0.134 62.9 ± 8.8
Clinical state
HNC 92 (53:39) 0.852 ± 0.130 60.5 ± 7.5
SCD 17(10:7) 0.925 ± 0.111 66.1 ± 9.5
MCI 15(9:6) 0.964 ± 0.098** 70.0 ± 9.2**
AD 38(26:12) 0.993 ± 0.089*** 65.1 ± 11.1*
HNC healthy normal control, SCD subjective cognitive decline, MCI mild cognitive impairment; AD Alzheimer’s disease dementia
*p value < 0.05, **p value < 0.01, ***p value < 0.001, a significance of the difference when compared with Healthy Normal Control by ANOVA using R package
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pathology of AD. Previous work using a transgenic
mouse model has also shown that blood-derived Aβ
induced AD pathology. The authors demonstrated
that Aβ from the AD transgenic mouse brain, which
entered the peripheral circulation of wild-type mice
after parabiosis surgery, had been transported into the
wild-type brain and accumulated over time to form
Aβ plaques [29].
When diagnosing AD clinically, cerebrospinal fluid Aβ
and amyloid positron emission tomography imaging are
widely used and strong methods for identifying amyloi-
dopathy in the brain. However, these methods have limi-
tations, such as invasiveness, inter-laboratory variability
and high cost [30].
Blood-based biomarkers, with advantages in terms of
low invasiveness and low cost, can serve as an alterna-
tive for AD assessment. Validated blood-based bio-
markers could be helpful in the diagnosis, monitoring of
patients and subject screening in clinical trials [30–32].
Because of these advantages, most clinicians prefer
blood-based biomarkers. However, plasma levels of pro-
teins associated with AD are much lower than CSF, and
this makes accurate and reliable measurements difficult
when conventional enzyme-linked immunosorbent as-
says are used. Several sensitive methods have been pro-
posed. The ABtest is one of these methods of measuring
free and total Aβ 42/40 plasma ratios, currently being
used in a research capacity [33]. The SIMOA technology
Table 2 Anatomic labelling of Montreal Neurological Institute (MNI) coordinates, maximal intensity and p value in voxel level
correlated to blood Aβ oligomerization
MNI coordinates Labels t value z value p value
(FWE-corr)x y z
− 60 − 51 2 Temporal_Mid_L 6.217 5.871 0.000
− 56 − 57 39 Parietal_Inf_L 5.925 5.621 0.000
− 50 − 60 − 9 Temporal_Inf_L 5.769 5.487 0.000
3 − 77 − 8 Lingual_R 5.881 5.583 0.000
0 − 63 11 Calcarine_L 5.731 5.454 0.000
− 2 − 72 9 Calcarine_L 5.614 5.352 0.001
0 − 38 39 Cingulum_Mid_L 5.609 5.348 0.001
0 − 48 38 Precuneus_L 5.435 5.196 0.002
− 3 − 36 50 Cingulum_Mid_L 4.879 4.702 0.015
− 9 − 2 − 15 Amygdala_L 5.449 5.208 0.002
5 2 − 11 Olfactory_L 5.314 5.089 0.003
− 14 − 3 − 26 ParaHippocampal_L 5.028 4.835 0.009
65 − 41 − 12 Temporal_Mid_R 5.334 5.107 0.002
60 − 53 − 6 Temporal_Mid_R 5.236 5.020 0.004
− 59 − 8 35 Postcentral_L 5.289 5.067 0.003
− 60 − 5 21 Postcentral_L 5.265 5.046 0.003
21 2 − 20 ParaHippocampal_R 5.036 4.842 0.008
33 − 2 − 21 Amygdala_R 4.777 4.609 0.023
32 2 − 29 Amygdala_R 4.697 4.537 0.030
− 62 − 23 14 Rolandic_Oper_L 5.006 4.815 0.009
− 62 − 32 18 Temporal_Sup_L 4.753 4.588 0.025
51 − 59 − 18 Temporal_Inf_R 5.002 4.812 0.009
54 − 47 − 23 Temporal_Inf_R 4.680 4.522 0.032
63 − 35 30 SupraMarginal_R 5.000 4.810 0.010
63 − 44 29 SupraMarginal_R 4.737 4.574 0.026
33 − 66 44 Angular_R 4.965 4.778 0.011
33 − 65 53 Parietal_Sup_R 4.633 4.480 0.038
63 − 15 − 5 Temporal_Sup_R 4.901 4.721 0.014
− 32 − 75 35 Occipital_Mid_L 4.788 4.619 0.022
L left, R right, Sup superior, Mid middle, Inf inferior, Oper operculum
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can also quantify lower levels of plasma molecules, such
as p-tau181 and Aβ using ultrasensitive immunoassay
[34, 35]. Immunomagnetic reduction (IMR) assays also
detect the molecules in plasma [36]. Measuring plasma
Aβ, tau and p-tau using these techniques would be
promising in distinguishing AD from those with subject-
ive cognitive decline, but equipment is required [34, 37].
Another approach is MDS-OAβ, which measures the Aβ
oligomerization instead of measuring Aβ species in
plasma [10]. It has been shown to correlate well with con-
ventional AD biomarkers such as CSF Aβ42 [11], C-Pitts-
burgh compound B positron emission tomography
standardized uptake value ratio, CSF phosphorylated tau
and CSF total tau [11]. Unlike other test methods, it mea-
sures Aβ oligomers. With accumulating evidences reveal-
ing soluble Aβ oligomers as the major toxic agent in AD
pathology, researchers have been trying to develop a way
to measure Aβ oligomers in the blood. We used this
method to measure the Aβ oligomerization in blood and
its correlation with brain atrophy.
We also observed volume changes in WM as well as
in GM. WM volume reduction was also observed near
GM volume reduction areas, the left temporal lobe, the
lower parietal lobe and the insula area. WM volume
A
B
Fig. 2 Grey matter (a) and white matter (b) volume reduction correlated with Aβ oligomerization measured with MDS-OAβ (n = 162, corrected
for age and total intracranial volume, family-wise error (FWE) < 0.05)
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changes in Alzheimer’s patients appear to be secondary
to Wallerian degeneration of fibre due to neuronal loss
in the association cortex [38, 39]. These changes are also
a supportive finding that MDS-OAβ levels in the blood
are related to changes in brain structure. However, the
limitation of this study is that we could not suggest the
severity and time sequence of the lesions correlated with
MDS-OAβ in WM or GM. To get the answer, further
studies are needed.
In this study, there was a good correlation between
MDS-OAβ levels in the blood and GM and WM atrophy
of the brain; however, it was not identified whether the
Aβ oligomerization in the blood was related to the cause
of brain atrophy in the form of AD. In order to add cer-
tainty, further longitudinal studies are to follow, and
more specifically, studies on testing how brain MRI var-
ies with baseline levels of MDS-OAβ in the blood are
necessary. Furthermore, additional studies should be
conducted on determining whether oligomerization of
Aβ is dependent on health condition and whether it can
affect brain structure.
Conclusions
This VBM study found specific brain atrophy and its lo-
cations related to MDS-OAβ of plasma. The significant
volume reduction was observed at the bilateral hippo-
campus, temporal, medial and dorsolateral parietal re-
gions (FWE < 0.05) where typical AD pathologic changes
are found. Higher MDS-OAβ could be related to AD
brain degeneration, and this warrants further
investigation.
Additional files
Additional file 1: Figure S1. Grey matter volume reduction in the
Alzheimer’s disease group (n = 39) compared to healthy normal control
(n = 92) (corrected for age and total intracranial volume, family-wise error
(FWE) < 0.01). (TIF 504 kb)
Additional file 2: Figure S2. The means of Multimer Detection System-
Oligomeric Aβ of healthy normal control (HNC), subjective cognitive de-
cline (SCD), mild cognitive impairment (MCI) and Alzheimer’s disease de-
mentia (AD) (expressed by mean dot and standard error bar). (TIF 125 kb)
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